








 |
CGMH
Administration
Center |
No.199, Tunghwa Rd.,
Taipei, Taiwan, R.O.C |

886-2-27135211 |
|
|
|
Quantitative Analysis of Chimerism after
Allogeneic Peripheral Blood Stem Cell Transplantation |
|
Ding-Ping Chen, MS
Kuo-Chien Tsao, BS
Po-Nan Wang1, MD
Ching-Ping Tseng2, PhD
Chien-Feng Sun, MD
|
 |
 |
|
Background: For peripheral blood stem cell transplantation
(PSCT), several engraftment analysis methods have been performed
including detection of restriction fragment length polymorphisms
and amplification of polymorphic genetic loci. To facilitate
monitoring of the engraftment, a quantitative, non-isotopic
method using a short tandem repeat (STR) marker has been set
up in our laboratory.
Methods: DNAs from pretransplant recipients and donors were
amplified with the AmpFlSTR Profiler Plus kit that contains
9 STR markers. The fluorescent polymerase chain reaction products
were then fractionated on polyacrylamide gels in an ABI PRISM
377 DNA sequencer. Results were analyzed using GeneScan 2.1
software. We selected the best markers as informative alleles
which can distinguish donor from recipient. For quantitative
analysis of the engraftment, we prepared a mixed chimeric
sample by mixing pretransplant recipient and donor DNAs in
different ratios to produce a standard curve. After amplifying
the posttransplant recipient DNA, we were able to detect the
extent of engraftment by interpolating the percent peak area
of the informative alleles from this standard curve.
Results: We retrospectively analyzed 10 patients who had received
allogeneic PSCT. Two of them showed some degree of mixed chimerism
indicating leukemic relapse. In case one, 38.7% of the recipient
DNA was first detected in the third month after PSCT. In case
two, 6.5% of the recipient DNA was first detected in the tenth
month after PSCT.
Conclusion: In summary, this method provides an accurate,
quantitative, and early assessment of mixed chimerism in posttransplant
patients. Such information may be useful to guide implementation
of additional treatment to circumvent graft failure or relapse
in the future.
(Chang Gung Med J 2002;25:734-42)
Key words: peripheral blood stem cell transplantation (PSCT),
quantitative short tandem repeats (STRs), mixed chimerism.
At present, allogeneic peripheral blood stem cell transplantation
(PSCT) is considered the best therapeutic option for patients
with severe aplastic anemia, severe combined immunodeficiency
disease, and leukemia. Detection of the extent of chimerism
after transplantation is an important method for monitoring
the engraftment of donor cells, thus allowing early detection
of graft failure. In the past, clinical physicians used cytogenetic
analysis or erythrocyte phenotyping to assess the extent of
chimerism. Recently, several approaches have been published
based on polymorphic DNA loci, such as restriction fragment
length polymorphisms, variable number tandem repeats, and
short tandem repeats (STRs).(1-3) The use of these markers
not only allows an assessment of the extent of chimerism but
also requires a very small amount of sample. Because STRs
are interspersed throughout the genome and commercial applications
are available, the use of STR loci has become a frequently
used medical technology for the study of engraftment. However,
the method is often limited by its ability to discriminate
between donors and recipients. To facilitate the monitoring
of peripheral blood stem cell engraftment, we developed a
novel approach using a multiplex polymerase chain reaction
(PCR) amplification of 9 STR loci and the amelogenin locus
which provides a rapid, accurate, and quantitative way to
determine the extent of chimerism after allogeneic PSCT.
METHODS
Patient samples
This retrospective study included 10 patients who received
allogeneic PSCT at Chang Gung Memorial Hospital. Patient details
are shown in Table 1.
Sample preparation
Peripheral blood samples were collected from a donor and recipient
before allogeneic PSCT and from the recipient at regular intervals
after the procedure. Genomic DNA was extracted from fresh
blood samples using a QIAamp DNA mini kit (QIAGEN, Hidden,
Germany).
Preparation of mixed chimeric DNA reconstructions
Before quantitative analysis of peripheral blood stem cell
engraftment, we first had to prepare pre-PSCT recipient and
donor DNAs in varying ratios of between 0% and 100% to produce
a standard curve for every individual case. A reconstruction
consisting of mixtures of varying percentages of pretransplant
recipient and donor DNAs represented the degree of amplification
of each allele in a mixed chimeric posttransplant sample.
In these reconstructions, while the percentages of donor and
recipient DNA changed relative to each other, the total amount
of DNA in the reconstruction remained constant.
STR amplification
We used the AmpFlSTR Profiler Plus PCR amplification kit (Applied
Biosystems, CA, USA) to perform STR-PCR. The tetranucleotide
STR loci amplified in this reaction included: D3S1358, vWA,
and FGA(4-6) (all labeled with 5-FAM); CSF1PO, TPOX, and TH01(7-9)
(all labeled with JOE); and D5S818, D13S317, and D7S820(10,11)
(all labeled with NED). In addition, the amelogenin locus
was analyzed, which discriminates between X and Y chromosomes
(labeled with JOE). For each PCR reaction, the final volume
was 25 ml and included 5 ng of DNA as recommended by the manufacturer.
The cycle conditions were: 95 oC for 11 min, followed by 28
cycles of 94 oC for 1 min, 59 oC for 1 min, and 72 oC for
1 min. The final elongation step was 45 min at 60 oC.
Electrophoresis and GeneScan analysis
The amplified PCR products were separated and detected using
an ABI377 automated DNA sequencer (Applied Biosystems). A
denaturing polyacrylamide gel containing 10X TBE, 6 M urea,
and 5% Long Ranger gel solution (FMC Biosystems, Maine, USA)
was used. For each sample, an internal size standard (GeneScan
Rox 500, ABI, Warrington, UK) and a formamide loading dye
solution were added. After denaturation, 1.5 £gl of this mixture
was loaded onto the gel, which was run for 2 h at 2.2 kV and
56 oC. Then the results were analyzed using the GeneScan 2.1
software.
Calculation of mixed chimerism
The recipient percentage peak area of the reconstruction samples
was calculated and plotted versus the percentage of recipient
DNA amplified to determine the engraftment of the posttransplant
samples. The recipient percentage peak area was calculated
as follows: %Peak area = [(AR1+AR2)ĦÑ100%] / (AD1+AD2+AR1+AR2),(12)
where A is the peak area; D is the donor alleles; and R is
the recipient alleles (Fig. 1). In cases of shared alleles,
only the informative alleles (i.e., those that distinguish
donor from recipient) were used in the calculation. We detected
the extent of engraftment or relapse by interpolating the
peak area of the informative alleles using this standard curve,
and the engraftment or relapse was expressed as either percent
donor or percent recipient DNA.
RESULTS
Precision, accuracy, and the standard curve
Because shorter alleles may amplify more efficiently than
longer alleles, it is important to simulate a range of mixed
chimerism that might be encountered in actual clinical posttransplant
samples. We performed dilution experiments in order to test
the linearity, reproducibility, precision, and sensitivity
of the STR-PCR for quantitative assessment of mixed chimerism.
Figure 2 shows the GeneScan data for the reconstruction samples
in this experiment. The donor peak showed increasing donor
allele peak area with increasing percentage of donor DNA.
Conversely, the upper recipient allele peak area decreased
as the percentage of recipient DNA decreased. The percent
peak area data for the informative alleles of the reconstruction
samples were calculated and used to plot a standard curve
(Fig. 3). Although the donor peak area of the standard curve
for each marker was directly proportional to the percent of
donor DNA added, the curve for each locus varied slightly.
Because amplification of the alleles differed from each other,
this variation emphasizes the importance of preparing standard
curves for the informative markers for each set of samples.
Sensitivity
In dilution experiments for plotting the standard curve, a
minor cell population representing 5% was reproducibly detected.
Even below 5%, signals could be found depending on the constellation
of peaks present. In other words, alleles for which 1 individual
was homozygous could be seen down to 1%. In addition to this,
the use of multiple alleles increased the reliability of results,
because of the higher chance of encountering an informative
peak constellation.
Informative STR alleles
There were many combinations of donor and recipient alleles,
and some of these combinations were informative for the detection
of recipient alleles, whereas others were not. Although some
loci were technically informative, they were not optimal for
use in determining mixed chimerism because of the existence
of stutter bands that appeared predominantly as 2 minor peaks
alongside the major allele peaks. In general, stutter peaks
are 1 repeat smaller or larger than the major allele peaks
and typically 10% or less than the area of the major allele.
They can influence the choice of informative loci for engraftment
analysis.
Clinical samples
Clinical DNA samples from the panel of 10 transplant patients'
peripheral blood cells were amplified for STR markers. Information
on the patients is given in Table 1. Figure 4 uses 1 of these
patients as an example. Donor and patient pretransplant samples
were found to be informative with D18S51. The D18S51 markers
were sized and genotyped with the D18S51 allelic ladder from
the Applied Biosystems AmpFlSTR Profiler Plus kit. Of the
10 patients examined, all patients showed complete engraftment
after PBST, but the recipient DNA in 2 patients appeared to
relapse after a period of time (Fig. 5). One recipient's DNA
appeared at 3 months post-transplantation, while the other
appeared after 10 months. In the first relapsed recipient,
interpolation of the reconstruction plot shows that 27.82%
of the recipient peak area of the posttransplant sample corresponded
to 38.7% of the recipient DNA (Fig. 6). The other showed that
1.67% of the recipient peak area of the posttransplant sample
corresponded to 6.5% of the recipient DNA.
DISCUSSION
Peripheral blood stem cell transplantation has been established
as a lifesaving procedure in selected hematologic malignancies
and bone marrow failure syndromes, and it may be valuable
in other types of neoplastic disease. Usually, relapse is
a significant cause of transplantation failure. Because most
relapses occur by expansion of a surviving leukemic clone
of recipient origin, early detection of the progressive reappearance
of recipient cells by bone marrow engraftment analysis may
help to predict clinical relapse. For patients with relapse
of chronic myelogenous leukemia, the effectiveness of adoptive
immunotherapy by donor lymphocyte infusion to produce clinical
remission has been well documented.(13-16) With acute leukemia,
a second PSCT is a reasonable therapeutic approach for the
treatment of a relapse. So it is necessary to carry out peripheral
blood stem cell engraftment analysis of allogeneic PSCT patients
to confirm the engraftment and to detect mixed chimerism or
recipient relapse after transplantation.
DNA polymorphisms are used to monitor engraftment after transplantation
from a related or unrelated donor. DNA polymorphisms are not
useful after autologous BMT. If the donor is an identical
twin, DNA polymorphisms are not useful, either. The most valuable
polymorphism for this purpose is caused by variations in certain
repeated sequences that are known as short tandem repeats
(STRs). An informative STR locus is one for which at least
1 recipient allele has a different number of repeats than
the donor allele(s). Because the recipient and donor are often
related, they share many alleles. Therefore, multiple STR
loci need to be tested to identify 1 or more informative loci.(17)
The simultaneous amplification of multiple loci in a single
reaction tube facilitates the identification of informative
loci.
Although some loci are technically informative, they might
not be optimal for the determination of mixed chimerism primarily
because of the existence of stutter bands that appear predominantly
as 2 minor peaks alongside the major allele peaks. The minor
peaks are predominantly 1 repeat smaller or larger than the
major allele peak. Stutter peaks have been proposed to result
from slipped strand mispairing during PCR amplification,(18)
which results in a peak that is 1 repeat smaller or larger
than the major allele peak. The existence of stutter peaks
influences the choice of informative loci for engraftment
analysis. In a state of recipient DNA relapse, the percentage
of recipient DNA is less than 5% to 10%, which is the same
size as a typical stutter peak. Hence it is necessary to use
the following criterion to choose the best locus: the recipient-specific
allele must be at least 2 repeats larger or smaller than the
nearest donor allele.
When an informative locus is selected, thee STR-PCR method
can be used to qualitatively evaluate the engraftment.(3,12,19,20)
A quantitative method for BME analysis using fluorescently
labeled primers for PCR amplification of individual VNTR and
STR loci was first described in 1995 by Scharf et al.(12)
An electrical peak area for each end-labeled fragment detected
is directly proportional to the number of DNA molecules present.
To simulate a posttransplant MC or a relapsed state, we mixed
2 different DNA samples that displayed recipient and donor
in various ratios of between 0% and 100% using the same total
amount of 5 ng DNA to prepare the amplification reconstruction
standard curves.
Because shorter alleles may amplify more efficiently than
longer alleles, it is often not possible to use a simple visual
estimation of the peak intensity to accurately determine the
extent of mixed chimerism. In addition, it is critical to
determine engraftment because of the potential for preferential
amplification in mixtures of alleles. These preferential amplification
effects depend on a variety of factors: the amount of DNA
or enzyme used, the inherent efficiency of the amplification
system, and the number and the relative size difference of
the alleles present in the sample. We have found that the
reconstruction standard curves obtained for a specimen can
vary among different markers. In addition, different donor
or recipient samples can produce different standard curves
for the same marker. So it is very important to establish
individual reconstruction standard curves for each marker
in each donor-recipient couple.
From our experience in preparing standard curves, we found
that the sensitivity of detection of small percentages of
recipient DNA is related to the amount of genomic DNA in the
PCR reaction. The use of 10 to 15 ng of DNA may improve the
sensitivity of detecting small amounts of recipient cells
by sampling more DNA, but this amount often results in nonspecific
peaks that ultimately decrease the sensitivity by increasing
the background, especially in multiplex reactions. The use
of 1 to 3 ng of DNA generally gives a clean baseline above
which recipient-specific peaks can easily be seen, but the
sensitivity is lower. As a result of these findings, we routinely
use 5 ng of DNA for PCR amplification in engraftment analysis
to obtain the best results. In addition to this, we strongly
suggest that before interpreting a result as negative for
a recipient, it is important to carefully search at a low
scale for recipient-specific peaks.
Because relapsing cells are originally from bone marrow rather
than from peripheral blood cells, we also suggest that it
is better to use DNA of bone marrow cells to survey the engraftment
condition rather than using that of peripheral blood cells.
In fact in 1998, Bader presented bone marrow transplant data
in which the recipient DNA of only 2 of 7 patients could be
detected in bone marrow samples but not in peripheral blood.(19)
In addition to this, a longer time interval in the follow-up
of these patients after allogeneic PSCT is a major limitation
of the sensitivity of this assay. Consequently, it is better
to investigate patients at short time intervals. With frequent
monitoring, the detection of mixed chimerism by chimerism
analysis may alert clinicians to a high risk of relapse and
allow early intervention with rapid treatment using immunosuppression
or donor lymphocyte infusion therapy, or even a second PSCT.
Although many methods have been used for engraftment analysis,
PCR amplification of STR loci is the best choice for many
clinical laboratories because it is informative, quantitative,
relatively rapid, and sensitive.
In conclusion, the greatest advantage of the STR-PCR procedure
over other published procedures seems to be its high rate
of discrimination. It represents an easy and accurate means
for quantitatively assessing relapsed DNA. Furthermore, the
use of fluorescent primers enables reliable quantification
without the need for additional densitometry. The method can
be especially helpful in monitoring patients undergoing transplantation.
|
 |
 |
|
REFERENCES
1. Lawler M, Humphries P, McCann SR. Evaluation of
mixed chimerism by in vitro amplification of dinucleotide
repeat sequences using the polymerase chain reaction. Blood
1991;77:2504-14.
2. Leclair B, Fregeau CJ, Aye MT, Fourney RM. DNA typing
for bone marrow engraftment follow-up after allogeneic transplant:
a comparative study of current technologies. Bone Marrow Transplant
1995;16:43-55.
3. Bader P, Holle W, Klingebiel T, Handgretinger R,
Niethammer D, Beck J. Quantitative assessment of mixed hematopoietic
chimerism by polymerase chain reaction after allogeneic BMT.
Anticancer Res 1996;16:1759-63.
4. Li H, Schmidt L, Wei MH, Hustad T, Lerman MI, Zbar
B, Tory K. Three tetranucleotide polymorphisms for loci: D3S1352,
D3S1358, D3S1359. Hum Mol Genet 1993;2:1327.
5. Kimpton C, Walton A, Gill P. A further tetranucleotide
repeat polymorphism in the vWF gene. Hum Mol Genet 1992;1:287.
6. Mills KA, Even D, Murray JC. Tetranucleotide repeat
polymorphism at the human alpha fibrinogen locus (FGA). Hum
Mol Genet 1992;1:779.
7. Edwards A, Hammond HA, Jin L, Laskey CT, Chakraborty
R. Genetic variation at five trimeric and tetrameric tandem
repeat loci in four human population groups. Genomics 1992;12:241-53.
8. Anker R, Steinbrueck T, Donis-Keller H. Tetranucleotide
repeat polymorphism at the human thyroid peroxidase (hTPO)
locus. Hum Mol Genet 1992;1:137.
9. Hammond HA, Jin L, Zhong Y, Laskey CT, Chakraborty
R. Evaluation of 13 short tandem repeat loci for use in personal
identification application. Am J Hum Genet 1994;55:175-89.
10. Hudson TJ, Stein LD, Gerety SS, Ma J, Castle AB,
Silva J, Slonim DK, Baptista R, Kruglyak L, Xu SH. An STS-based
map of the human genome. Science 1995; 270: 1945-54.
11. Green ED, Mohr RM, Idol JR, Jones M, Buckingham
JM, Deaven LL, Moyzis RK, Olson MV. Systematic generation
of sequence-tagged sites for physical mapping of human chromosomes:
application to the mapping of human chromosome 7 using yeast
artificial chromosomes. Genomics 1991;11:548-64.
12. Scharf SJ, Smith AG, Hansen JA, McFarland C, Erlich
HA. Quantitative determination of bone marrow transplant engraftment
using fluorescent polymerase chain reaction primers for human
identity markers. Blood 1995;85: 1954-63.
13. Collins RH, Jr., Shpilberg O, Drobyski WR, Porter
DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie
C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis
J. Donor leukocyte infusion in 140 patients with relapsed
malignancy after allogeneic bone marrow transplantation. J
Clin Oncol 1997;15:433-44.
14. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose
G, Brehm G, Heim M, Wilmanns W. Donor leukocyte transfusion
for treatment of recurrent chronic myelogenous leukemia in
marrow transplant patients. Blood 1990;76:2462-5.
15. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein
B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L,
Niederwieser D. Graft-versus-leukemia effect of donor lymphocyte
transfusions in marrow grafted patients. Blood 1995;86:2041-50.
16. Porter DL, Roth MS, McGarigle C, Ferrara JL, Antin
JH. Induction of graft-versus-host disease as immunotherapy
for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100-6.
17. Kimpton CP, Gill P, Walton A, Urquhart A, Millican
ES, Adams M. Automated DNA profiling employing multiplex amplification
of short tandem repeat loci. PCR Methods Appl 1993;3:13-22.
18. Walsh PS, Fildes NJ, Reynolds R. Sequence analysis
and characterization of stutter products at the tetranucleotide
repeat locus vWA. Nucleic Acids Res 1996;24:2807-12.
19. Bader P, Beck J, Frey A, Schlegel PG, Hebarth H,
Handgretinger R, Einsele H, Niemeyer C, Benda N, Faul C, Kanz
L, Niethammer D, Klingebiel T. Serial and quantitative analysis
of mixed hematopoietic chimerism by PCR in patients with acute
leukemias allows the prediction of relapse after allogeneic
BMT. Bone Marrow Transplant 1998;21:487-95.
20. Bader P, Holle W, Klingebiel T, Handgretinger R,
Benda N, Schlegel PG, Niethammer D, Beck J. Mixed hematopoietic
chimerism after allogeneic bone marrow transplantation: the
impact of quantitative PCR analysis for prediction of relapse
and graft rejection in children. Bone Marrow Transplant 1997;19:697-702.
|
 |
 |
|
From the Clinical Pathology; 1Division of Hematology-Oncology,
Department of Internal Medicine, Chang Gung Memorial Hospital,
Taipei; 2School of Medical Technology, Chang Gung University,
Taoyuan.
Received: May 30, 2002; Accepted: Jul. 26, 2002
Address for reprints: Dr. Chien-Feng Sun, Department of Clinical
Pathology, Chang Gung Memorial Hospital. 5, Fu-Shing Street,
Kweishan 333, Taoyuan, Taiwan, R.O.C. Tel.: 886-3-3281200
ext. 2554; Fax: 886-3-3284376; E-mail: suncgj@cgmh.org.tw
|
|